Technical Analysis for HGEN - Humanigen, Inc.

Grade Last Price % Change Price Change
B 16.71 -1.82% -0.31
HGEN closed down 8.0 percent on Wednesday, May 12, 2021, on 37 percent of normal volume.
Earnings due: May 19
*** please verify all earnings dates ***

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Down
Historical HGEN trend table...

Date Alert Name Type % Chg
20 DMA Support Bullish -1.82%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -1.82%
Wide Bands Range Expansion -1.82%
Wide Bands Range Expansion -9.68%
Wide Bands Range Expansion -7.48%
Overbought Stochastic Strength -7.48%
NR7 Range Contraction -13.69%
Stochastic Reached Overbought Strength -13.69%
Wide Bands Range Expansion -13.69%
Overbought Stochastic Strength -13.69%
Older End-of-Day Signals for HGEN ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Fell Below 50 DMA 9 minutes ago
50 DMA Support about 2 hours ago
Down 1% about 2 hours ago
Fell Below Previous Day's Low about 2 hours ago
60 Minute Opening Range Breakdown about 2 hours ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Humanigen, Inc. Description

Humanigen, Inc. is developing its portfolio of clinical and pre-clinical therapies for the treatment of cancers and infectious diseases via its novel, cutting-edge GM-CSF neutralization and gene-knockout platforms. We believe that our GM-CSF neutralization and gene-editing platform technologies have the potential to reduce the inflammatory cascade associated with coronavirus infection. The company's immediate focus is to prevent or minimize the cytokine release syndrome that precedes severe lung dysfunction and ARDS in serious cases of SARS-CoV-2 infection. The company is also focused on creating next-generation combinatory gene-edited CAR-T therapies using strategies to improve efficacy while employing GM-CSF gene knockout technologies to control toxicity. In addition, the company is developing its own portfolio of proprietary first-in-class EphA3-CAR-T for various solid cancers and EMR1-CAR-T for various eosinophilic disorders. The company is also exploring the effectiveness of its GM-CSF neutralization technologies (either through the use of lenzilumab as a neutralizing antibody or through GM-CSF gene knockout) in combination with other CAR-T, bispecific or natural killer (NK) T cell engaging immunotherapy treatments to break the efficacy/toxicity linkage, including to prevent and/or treat graft-versus-host disease (GvHD) in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). Additionally, Humanigen and Kite, a Gilead Company, are evaluating lenzilumab in combination with Yescarta® (axicabtagene ciloleucel) in patients with relapsed or refractory large B-cell lymphoma in a clinical collaboration.


Sector: Healthcare
Industry: Biotechnology
Keywords: Clinical Medicine Immune System Infectious Diseases Immunotherapy Treatment Of Cancer Cancers Lymphoma Gene Therapy Infection Dysfunction Coronavirus Transplantation Hematopoietic Stem Cell Cytokine Cytokines Chimeric Antigen Receptor T Cell Sars Gilead Sciences Host Disease Platform Technologies Treatment Of Cancers Graft Versus Host Disease Eosinophil Coronavirus Infection Cytokine Release Syndrome Solid Cancers

Is HGEN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 33.95
52 Week Low 3.9025
Average Volume 3,389,186
200-Day Moving Average 15.47
50-Day Moving Average 16.79
20-Day Moving Average 17.00
10-Day Moving Average 18.31
Average True Range 1.70
ADX 16.29
+DI 23.04
-DI 21.20
Chandelier Exit (Long, 3 ATRs ) 14.93
Chandelier Exit (Short, 3 ATRs ) 18.37
Upper Bollinger Band 20.57
Lower Bollinger Band 13.44
Percent B (%b) 0.5
BandWidth 41.91
MACD Line 0.43
MACD Signal Line 0.37
MACD Histogram 0.065
Fundamentals Value
Market Cap 878.51 Million
Num Shares 51.6 Million
EPS -0.09
Price-to-Earnings (P/E) Ratio -185.00
Price-to-Sales 0.00
Price-to-Book 15.12
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 19.27
Resistance 3 (R3) 19.51 19.01 18.90
Resistance 2 (R2) 19.01 18.43 18.89 18.77
Resistance 1 (R1) 18.01 18.08 17.76 17.77 18.64
Pivot Point 17.51 17.51 17.38 17.39 17.51
Support 1 (S1) 16.51 16.93 16.26 16.27 15.40
Support 2 (S2) 16.01 16.58 15.89 15.27
Support 3 (S3) 15.01 16.01 15.15
Support 4 (S4) 14.77